Premium
Inozyme Pharma Inc (INZY)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.16 | 5.53633217993 | 2.89 | 3.28 | 2.65 | 592433 | 2.93043307 | CS |
| 4 | 0.35 | 12.962962963 | 2.7 | 3.46 | 2.385 | 904393 | 2.79260831 | CS |
| 12 | -2.13 | -41.1196911197 | 5.18 | 5.59 | 2.385 | 477863 | 3.36959958 | CS |
| 26 | -1.3 | -29.8850574713 | 4.35 | 6.24 | 2.385 | 378499 | 4.06801756 | CS |
| 52 | -1.1 | -26.5060240964 | 4.15 | 7.795 | 2.385 | 452933 | 4.83381453 | CS |
| 156 | -4.72 | -60.7464607465 | 7.77 | 7.9996 | 0.991 | 470746 | 4.26818156 | CS |
| 260 | -14.88 | -82.9894032348 | 17.93 | 31.6499 | 0.991 | 341088 | 5.18525909 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
